Does using fidaxomicin to treat Clostridium difficile infection (CDI) reduce the recovery of C. difficile from faeces, patient's skin and the immediate environment compared to treatment with vancomycin or metronidazole?

Trial Profile

Does using fidaxomicin to treat Clostridium difficile infection (CDI) reduce the recovery of C. difficile from faeces, patient's skin and the immediate environment compared to treatment with vancomycin or metronidazole?

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Dec 2015 Accrual to date is 116% according to United Kingdom Clinical Research Network.
    • 05 Nov 2015 Accrual to date is 111% according to United Kingdom Clinical Research Network.
    • 05 Oct 2015 Accrual to date is 99% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top